A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Solmaz Sahebjam,Philippe L. Bedard,Vincent Castonguay,Z Chen,Michael Reedijk,Geoffrey Liu,Brenda Cohen,W-J Zhang,Blaise A. Clarke,Tong Zhang,Suzanne Kamel-Reid,Helen X. Chen,S. P. Ivy,Albiruni Ryan Abdul Razak,Amit M. Oza,E.X. Chen,Hal W. Hirte,A McGarrity,Lisa Wang,Lillian L. Siu,Sebastien J. Hotte +20 more
TL;DR: RO4929097 in combination with cediranib is generally well tolerated and preliminary evidence of antitumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation.
Journal ArticleDOI
Inhibition of the nuclear export receptor xpo1 as a therapeutic target for platinum resistant ovarian cancer
Ying Chen,Sandra Catalina Camacho,Thomas R. Silvers,Albiruni Ryan Abdul Razak,Nashat Y. Gabrail,John F. Gerecitano,Eva Kalir,Elena Pereira,Brad R. Evans,Susan J. Ramus,Fei Huang,Nolan Priedigkeit,Estefanía Rodríguez,Michael J. Donovan,Faisal Khan,Tamara Kalir,Robert Sebra,Andrew V. Uzilov,Rong Chen,Rileen Sinha,Richard Halpert,Jean-Noel Billaud,Sharon Shacham,Dilara McCauley,Yosef Landesman,Tami Rashal,Michael Kauffman,Mansoor Raza Mirza,Morten Mau-Sørensen,Peter Dottino,John A. Martignetti,John A. Martignetti +31 more
TL;DR: Evidence is provided that XPO1 inhibition represents a new therapeutic strategy for overcoming platinum resistance in women with ovarian cancer.
Journal ArticleDOI
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti,Anna Maria Frezza,Jean-Yves Blay,Elizabeth H. Baldini,Sylvie Bonvalot,Judith V.M.G. Bovée,Dario Callegaro,Paolo G. Casali,Ru Ru Chun ju Chiang,George D. Demetri,Elisabeth G. Demicco,Jayesh Desai,Mikael Eriksson,Hans Gelderblom,Suzanne George,Mrinal M. Gounder,Mrinal M. Gounder,Alessandro Gronchi,Abha A. Gupta,Rick L. Haas,Rick L. Haas,Andrea Hayes-Jardon,Peter Hohenberger,Kevin B. Jones,Robin L. Jones,Bernd Kasper,Akira Kawai,David G. Kirsch,Eugene S. Kleinerman,Axel Le Cesne,Jiwon Lim,María Dolores López,Roberta Maestro,Rafael Marcos-Gragera,Javier Martin Broto,Tomohiro Matsuda,Olivier Mir,Shreyaskumar Patel,Chandrajit P. Raut,Chandrajit P. Raut,Albiruni Ryan Abdul Razak,Damon R. Reed,Piotr Rutkowski,Roberta Sanfilippo,Marta Sbaraglia,Inga-Marie Schaefer,Dirk C. Strauss,Kirsten Sundby Hall,William D. Tap,William D. Tap,David Thomas,Winette T. A. van der Graaf,Winan J. van Houdt,Otto Visser,Margaret von Mehren,Andrew J. Wagner,Breelyn A. Wilky,Young-Joo Won,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Annalisa Trama +60 more
TL;DR: In this article, a list of ultra-rare sarcomas was defined as those with an incidence of ≤ 1 per 1,000,000 to include those entities whose rarity renders them extremely difficult to conduct well powered, prospective clinical studies.
Journal ArticleDOI
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Juneko E. Grilley-Olson,Philippe L. Bedard,Angelica Fasolo,Cornfeld Mark J,Cornfeld Mark J,Cornfeld Mark J,Leanne Cartee,Leanne Cartee,Albiruni Ryan Abdul Razak,Lee-Anne Stayner,Yuehui Wu,Yuehui Wu,R. Greenwood,R. Greenwood,R. Greenwood,Rajeshwar Singh,Rajeshwar Singh,Carrie B. Lee,Johanna C. Bendell,H. A. Burris,G. Del Conte,Cristiana Sessa,J. R. Infante +22 more
TL;DR: GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities, which may be due to overlapping toxicities precluding sufficient dose exposure.
Journal ArticleDOI
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Albiruni Ryan Abdul Razak,Sebastien J. Hotte,Lillian L. Siu,E.X. Chen,Hal W. Hirte,Jean Powers,W. Walsh,L-A Stayner,Anne Laughlin,V Novotny-Diermayr,J Zhu,Elizabeth Eisenhauer +11 more
TL;DR: The safety, dose-limiting toxicity, recommended phase II dose (RPTD), as well as pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SB939 in a daily × 5 schedule in advanced solid tumours are determined.